# Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

> **NCT05912816** · PHASE2 · RECRUITING · sponsor: **RenJi Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Upper Urinary Tract Urothelial Carcinoma
- Kidney Preservation
- HER-2 ADC
- PD-1antibody

## Interventions

- **DRUG:** RC48 Combined With Tislelizumab

## Key facts

- **NCT ID:** NCT05912816
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-10
- **Primary completion:** 2025-11-03
- **Final completion:** 2026-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05912816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05912816, "Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05912816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*